American Heart Journal
Volume 156, Issue 1 , Pages 71-77 , July 2008

N-terminal pro–brain natriuretic peptide testing in the emergency department: Beneficial effects on hospitalization, costs, and outcome

  • Joost H.W. Rutten, MD

      Affiliations

    • Department of Internal Medicine, Erasmus Medical College-University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Ewout W. Steyerberg, PhD

      Affiliations

    • Department of Public Health, Erasmus Medical College-University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Frans Boomsma, PhD

      Affiliations

    • Department of Internal Medicine, Erasmus Medical College-University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Jan L.C.M. van Saase, MD, PhD

      Affiliations

    • Department of Internal Medicine, Erasmus Medical College-University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Jaap W. Deckers, MD, PhD

      Affiliations

    • Department of Cardiology, Thoraxcenter, Erasmus Medical College-University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Henk C. Hoogsteden, MD, PhD

      Affiliations

    • Department of Pulmonary Medicine, Erasmus Medical College-University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Jan Lindemans, PhD

      Affiliations

    • Department of Clinical Chemistry, Erasmus Medical College-University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Anton H. van den Meiracker, MD, PhD

      Affiliations

    • Department of Internal Medicine, Erasmus Medical College-University Medical Center Rotterdam, Rotterdam, The Netherlands
    • Corresponding Author InformationReprint requests: Anton H. van den Meiracker, MD, PhD, Erasmus MC, Department of Internal Medicine, Room D 432, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.

Received 7 October 2007 ,Accepted 12 February 2008.

References 

  1. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70
  2. Sidney S, Sorel M, Quesenberry CP, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128:2068–2075
  3. Abroug F, Ouanes-Besbes L, Nciri N, et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med. 2006;174:990–996
  4. Alibay Y, Beauchet A, El Mahmoud R, et al. Plasma N-terminal pro–brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea. Biomed Pharmacother. 2005;59:20–24
  5. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail. 2004;6:301–308
  6. Berdague P, Caffin PY, Barazer I, et al. Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. Am Heart J. 2006;151:690–698
  7. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001;37:379–385
  8. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343:440–444
  9. Fleischer D, Espiner EA, Yandle TG, et al. Rapid assay of plasma brain natriuretic peptide in the assessment of acute dyspnoea. N Z Med J. 1997;110:71–74
  10. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–954
  11. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330–337
  12. Knudsen CW, Riis JS, Finsen AV, et al. Diagnostic value of a rapid test for B-type natriuretic peptide in patients presenting with acute dyspnoe: effect of age and gender. Eur J Heart Fail. 2004;6:55–62
  13. Lainchbury JG, Campbell E, Frampton CM, et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003;42:728–735
  14. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  15. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39:202–209
  16. Mueller T, Gegenhuber A, Poelz W, et al. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart. 2005;91:606–612
  17. Wang CS, FitzGerald JM, Schulzer M, et al. Does this dyspneic patient in the emergency department have congestive heart failure?. Jama. 2005;294:1944–1956
  18. Nohria A, Mielniczuk LM, Stevenson LW. Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol. 2005;96:32G–40G
  19. Siebert U, Januzzi JL, Beinfeld MT, et al. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol. 2006;98:800–805
  20. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647–654
  21. Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med. 2006;166:1081–1087
  22. Moe GW, Howlett J, Januzzi JL, et al. N-terminal pro–B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007;115:3103–3110
  23. Yeo KT, Wu AH, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta. 2003;338:107–115
  24. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000;19:3219–3236
  25. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100
  26. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed?. Bmj. 2000;320:1197–1200
  27. Nielsen LS, Svanegaard J, Klitgaard NA, et al. N-terminal pro–brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail. 2004;6:63–70

 This research project was funded by a grant of the Erasmus MC Medical Research Advisory Committee (Mrace).

PII: S0002-8703(08)00219-6

doi: 10.1016/j.ahj.2008.02.021

American Heart Journal
Volume 156, Issue 1 , Pages 71-77 , July 2008

Article Tools

* Image Usage & Resolution